Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Shabaneh TB, Stevens AR, Stull SM, Shimp KR, Seaton BW, Gad EA, Jaeger-Ruckstuhl CA, Simon S, Koehne AL, Price JP, Olson JM, Hoffstrom BG, Jellyman D, Riddell SR
J Immunother Cancer. 2024 Feb 7;12(2):e008566. doi: 10.1136/jitc-2023-008566.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.